Image

Global Bile Duct Cancer Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Bile Duct Cancer Market, By Product (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Application (Hospitals, Clinics, Others), Disease Indication (Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2029.

Bile Duct Cancer Market

Global Bile Duct Cancer Market Analysis and Size

In recent years, the bile duct cancer market is anticipated to grow rapidly during the forecast period. Bile duct carcinoma is a rare disease that can affect both the inside and outside of the liver (intrahepatic and extrahepatic) (extrahepatic). The number of reported cases is lower. However, the overall rate of development appears to be higher, as numerous cancer patients are misdiagnosed with other cancers. According to the American Cancer Society, the condition is particularly common in Southeast Asian countries due to parasite infection, which can develop cancer in the bile duct region of the human body.

Cholangiocarcinoma, commonly known as bile duct cancer, is a rare condition in which malignant cancer cells grow in the bile duct. The bile duct comprises a series of tubes that connect the liver, small intestine, and gall bladder. The tiniest ducts join together to produce the hepatic duct, which leads to the liver. Bile travels from the liver to the gall bladder via the hepatic duct and the hepatic duct. Intrahepatic bile duct cancer and extrahepatic bile duct cancer are the two forms of bile duct cancer.

Data Bridge Market Research analyses that the bile duct cancer market was valued at USD 185.4 million in 2021 and is expected to reach USD 330.66 million by 2029, registering a CAGR of 7.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Application (Hospitals, Clinics, Others), Disease Indication (Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AbbVie Inc. (US), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Intercept Pharmaceuticals (US), Kyowa Kirin Co., Ltd. (Japan), Delcath Systems, Inc. (US), Accord Healthcare (US), CONMED Corporation (US), Boston Scientific Corporation (US), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Bile Duct Cancer Market Dynamics

Drivers

  • Increased Exposure To Toxic Chemicals

Increased exposure to toxic chemicals for printing and other applications is having a negative impact on industrial workers. As a result of these considerations, bile duct cancer treatment is expected to grow in popularity across the healthcare industry.     

  • Increasing Investment For Healthcare Infrastructure

Another significant factor influencing the growth rate of bile duct cancer market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the bile duct cancer market. Other factors such as rise in prevalence rate of bile duct cancer will positively impact the bile duct cancer market's growth rate. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will expand the bile duct cancer market. Along with this, increasing prevalence of liver fluke will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bile duct cancer market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the bile duct cancer market during the forecast period.

Restraints/Challenges Global Bile Duct Cancer Market

On the other hand, the high cost associated with the treatment of bile duct cancer will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the bile duct cancer market. Additionally, the impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This bile duct cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bile duct cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to the World Health Organization, cancer kills almost 8.3 million people. Bile duct cancer is an uncommon type of cancer, with only about 2,500 new cases detected each year in the United States. Cholangiocarcinoma, commonly known as bile duct cancer, mainly affects persons over the age of 50, however, it can strike anyone at any age.

Bile duct cancer market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bile Duct Cancer Market

In collaboration with governments throughout the world, pharmaceutical and biotech businesses are working to combat the COVID-19 pandemic, from vaccine development to logistics planning. There are around 115 vaccine candidates and 155 compounds in the Research and innovation pipeline. In addition, frequently used medications notably hydroxychloroquine have seen a tremendous increase for COVID-19 treatment. Due to the increased demand for these treatments, producers of COVID-19 management medications have a lot of potential because several wealthy countries are running out of them. Therefore, due to the need for vaccines and therapeutic medications for COVID-19, the pharmaceutical and biotechnology industries are anticipated to rise significantly in the future. As a result, the bile duct cancer medication industry is projected to have a considerable impact.

Recent Development

  • In April 2020, the U.S. Food and Drug Administration had approved the first targeted treatment for patients with cholangiocarcinoma called Pemazyre (pemigatinib). Pemazyre's approval was based on the findings of a clinical trial in which 107 patients with locally advanced or metastatic cholangiocarcinoma who had previously received therapy and had a FGFR2 fusion or rearrangement were enrolled.

Global Bile Duct Cancer Market Scope

The bile duct cancer market is segmented on the basis of product, disease indication, distribution channel and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • 5-fluorouracil (5-FU)
  • Gemcitabine
  • Cisplatin
  • Capecitabine
  • Oxaliplatin

Based on product, the bile duct cancer market is segmented into 5-fluorouracil (5-FU), gemcitabine, cisplatin, capecitabine and oxaliplatin.

Application

  • Hospitals
  • Clinics
  • Others

Based on application, the bile duct cancer market is segmented into hospitals, clinics and others.

Disease Indication

  • Intrahepatic Bile Duct Cancer
  • Extrahepatic Bile Duct Cancer

Based on disease indication, the bile duct cancer market is segmented into intrahepatic bile duct cancer, extrahepatic bile duct cancer. Extrahepatic bile duct cancer is further segmented into perihilar bile duct cancer, distal extrahepatic bile duct cancer.

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on distribution channel, the bile duct cancer market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

Bile Duct Cancer Market Regional Analysis/Insights

The bile duct cancer market is analysed and market size insights and trends are provided by country, product, disease indication, distribution channel and application as referenced above.

The countries covered in the bile duct cancer market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the bile duct cancer market because of the prevalence of bile cancer and the growing number of ongoing research activities in this region. 

Asia-Pacific is expected to grow during the forecast period due to rising number of awareness programs and increase in public and private investment in this region. Also, rapid and easy production approval process will enhance the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Bile Duct Cancer Market Share Analysis

The Bile duct cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bile duct cancer market.

Some of the major players operating in the bile duct cancer market are:

  • Johnson & Johnson Private Limited (US)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • AbbVie Inc. (US)
  • Novartis AG (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Eli Lilly and Company (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Intercept Pharmaceuticals (US)
  • Kyowa Kirin Co., Ltd. (Japan)
  • Delcath Systems, Inc. (US)
  • Accord Healthcare (US)
  • CONMED Corporation (US)
  • Boston Scientific Corporation (US)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (US)
  • Merck & Co., Inc. (US)


SKU-
Why Choose Us


Frequently Asked Questions

The Market Value for Bile Duct Cancer Market is expected USD 330.66 million by 2029.
The Bile Duct Cancer Market is to Grow at a CAGR of 7.50% During the Forecast Period of 2022 to 2029.
Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland) are the Major Companies Operating in Bile Duct Cancer Market.
The Countries Covered in the Bile Duct Cancer Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
The Bile Duct Cancer Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.